<?xml version="1.0" encoding="UTF-8"?>
<p id="Par42">Production of the phase 3 drug substance and drug product lots provides an opportunity for establishing a dataset suitable for the process validation package of the license application. Appropriate sampling, testing and data analysis of the phase 3 lots could preclude the need for a separate qualification campaign executed months later, which is the typical practice today, accelerating the license application
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>
 </sup>. This would require that there be no significant process changes after the phase 3 campaign. After licensure, continuous process verification would be employed to manage the early years of commercial production
 <sup>
  <xref ref-type="bibr" rid="CR27">27</xref>
 </sup>.
</p>
